News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
703,122 Results
Type
Article (39979)
Company Profile (248)
Press Release (662895)
Multimedia
Podcasts (52)
Webinars (12)
Section
Business (205326)
Career Advice (2026)
Deals (35565)
Drug Delivery (98)
Drug Development (81236)
Employer Resources (172)
FDA (16261)
Job Trends (14902)
News (346834)
Policy (32713)
Tag
Academia (2562)
Accelerated approval (5)
Adcomms (20)
Allergies (86)
Alliances (49554)
ALS (95)
Alzheimer's disease (1385)
Antibody-drug conjugate (ADC) (133)
Approvals (16259)
Artificial intelligence (265)
Autoimmune disease (22)
Automation (17)
Bankruptcy (362)
Best Places to Work (11659)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (175)
Bladder cancer (79)
Brain cancer (27)
Breast cancer (290)
Cancer (2323)
Cardiovascular disease (180)
Career advice (1688)
Career pathing (30)
CAR-T (156)
Cell therapy (437)
Cervical cancer (20)
Clinical research (66225)
Collaboration (856)
Company closure (2)
Compensation (566)
Complete response letters (19)
COVID-19 (2591)
CRISPR (41)
C-suite (252)
Cystic fibrosis (109)
Data (2324)
Decentralized trials (2)
Denatured (20)
Depression (44)
Diabetes (275)
Diagnostics (6430)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (103)
Drug shortages (25)
Duchenne muscular dystrophy (96)
Earnings (87572)
Editorial (39)
Employer branding (21)
Employer resources (146)
Events (113525)
Executive appointments (747)
FDA (17638)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (768)
Gene editing (109)
Generative AI (20)
Gene therapy (314)
GLP-1 (724)
Government (4454)
Grass and pollen (4)
Guidances (158)
Healthcare (18918)
Huntington's disease (24)
IgA nephropathy (27)
Immunology and inflammation (124)
Indications (29)
Infectious disease (2737)
Inflammatory bowel disease (143)
Inflation Reduction Act (8)
Influenza (52)
Intellectual property (98)
Interviews (314)
IPO (16608)
IRA (40)
Job creations (3649)
Job search strategy (1433)
Kidney cancer (10)
Labor market (43)
Layoffs (477)
Leadership (17)
Legal (7940)
Liver cancer (76)
Lung cancer (325)
Lymphoma (157)
Machine learning (9)
Management (58)
Manufacturing (328)
MASH (77)
Medical device (13469)
Medtech (13474)
Mergers & acquisitions (19527)
Metabolic disorders (708)
Multiple sclerosis (83)
NASH (16)
Neurodegenerative disease (95)
Neuropsychiatric disorders (27)
Neuroscience (1941)
NextGen: Class of 2025 (6541)
Non-profit (4487)
Now hiring (40)
Obesity (371)
Opinion (205)
Ovarian cancer (82)
Pain (93)
Pancreatic cancer (88)
Parkinson's disease (152)
Partnered (22)
Patents (244)
Patient recruitment (115)
Peanut (46)
People (57800)
Pharmaceutical (63)
Pharmacy benefit managers (19)
Phase I (20634)
Phase II (29182)
Phase III (21715)
Pipeline (1369)
Policy (148)
Postmarket research (2567)
Preclinical (8780)
Press Release (64)
Prostate cancer (108)
Psychedelics (30)
Radiopharmaceuticals (249)
Rare diseases (391)
Real estate (5917)
Recruiting (65)
Regulatory (22440)
Reports (47)
Research institute (2324)
Resumes & cover letters (355)
Rett syndrome (6)
RNA editing (5)
RSV (43)
Schizophrenia (72)
Series A (131)
Series B (87)
Service/supplier (11)
Sickle cell disease (52)
Special edition (16)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3589)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (50)
The Weekly (30)
Vaccines (704)
Venture capitalists (42)
Weight loss (238)
Women's health (36)
Worklife (16)
Date
Today (174)
Last 7 days (984)
Last 30 days (3118)
Last 365 days (32607)
2025 (11880)
2024 (35350)
2023 (40254)
2022 (51365)
2021 (55895)
2020 (54250)
2019 (46741)
2018 (35197)
2017 (32310)
2016 (31686)
2015 (37785)
2014 (31550)
2013 (26509)
2012 (28693)
2011 (29391)
2010 (27456)
Location
Africa (722)
Alabama (54)
Alaska (7)
Arizona (237)
Arkansas (13)
Asia (38235)
Australia (6212)
California (6412)
Canada (2065)
China (541)
Colorado (273)
Connecticut (280)
Delaware (158)
Europe (82633)
Florida (954)
Georgia (215)
Idaho (57)
Illinois (546)
India (25)
Indiana (322)
Iowa (11)
Japan (171)
Kansas (108)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (925)
Massachusetts (4769)
Michigan (225)
Minnesota (405)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (68)
New Hampshire (64)
New Jersey (1793)
New Mexico (29)
New York (1804)
North Carolina (998)
North Dakota (8)
Northern California (2827)
Ohio (211)
Oklahoma (14)
Oregon (34)
Pennsylvania (1426)
Puerto Rico (13)
Rhode Island (33)
South America (1108)
South Carolina (25)
South Dakota (1)
Southern California (2409)
Tennessee (105)
Texas (950)
United States (24035)
Utah (189)
Virginia (151)
Washington D.C. (64)
Washington State (563)
West Virginia (3)
Wisconsin (56)
703,122 Results for "cf pharmtech inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical WorkflowsKR-HT5 is based on Akoya’s PhenoImager® HT Platform
Akoya Biosciences, Inc., The Spatial Biology Company®, and Shanghai KR Pharmtech have jointly announced that KR-HT5, which Akoya Biosciences co-developed with Shanghai KR Pharmtech utilizing the PhenoImager HT technology as its foundation, has received premarket approval from China’s National Medical Products Administration to support next generation pathology clinical workflows.
May 2, 2024
·
4 min read
Press Releases
Solve M.E., Brain Inflammation Collaborative (BIC), ChronicleBio, Complex Disorders Alliance, and CareEvolution Launch Groundbreaking Partnership to Accelerate Research on ME/CFS, Long Covid, and IACCIs
April 30, 2025
·
6 min read
Press Releases
AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS
January 23, 2025
·
7 min read
Business
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced that Charles Lapp, MD, is joining the company to help lead its efforts to develop Ampligen (rintatolimod) as a potential treatment for Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID.
April 15, 2024
·
2 min read
BioVersys Awarded Non-Dilutive Funding From CF AMR Syndicate Collaborative Discovery Programme
BioVersys AG announced that it has received a non-dilutive award from the CF AMR Syndicate of up to £ 500,000, via a LifeArc funded Collaborative Discovery Programme award, to support the development of novel small molecules targeting difficult to treat non-tubercular mycobacteria lung disease in people with cystic fibrosis.
June 4, 2024
·
10 min read
Press Releases
Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency
January 7, 2025
·
8 min read
Press Releases
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway
January 13, 2025
·
9 min read
Press Releases
CF Foundation Invests Up to $15 million in ReCode Therapeutics to Develop a Gene Editing Therapy
November 19, 2024
·
2 min read
CF PharmTech, Inc. Closes a US $50M Series F Financing to Accelerate the Commercialization of its Inhalation Products.
CF PharmTech, Inc. (“CF PharmTech”) announced today that it has raised US $50M in Series F financing following its US $90M Series E financing in January of 2020, in total, successfully completing an equity investment deal of nearly US $140M within six months.
July 1, 2020
·
1 min read
CF PharmTech and Chengdu Shangyi Launch the “Home-Based Recovery Program for Discharged Covid-19 Patients” and Announce Today’s Global Release of the “R Plus Health” Free App
CF PharmTech, Inc. is a fully integrated pharmaceutical company in China specializing in the treatment of respiratory diseases.
February 1, 2021
·
2 min read
1 of 70,313
Next
